DIABLA: Dynamic Isoelectric/Anisotropy Binding Ligand Assay for Protein Target Discovery and Isolation
Methods of detecting an interaction between an analyte and a biomolecule using dynamic isoelectric focusing techniques and fluorescence anisotropy
Project Leaders: Luke Tolley, Matt McCarroll
Unit: College of Science, Dept. of Chemistry and Biochemistry
Executive Summary
This system is vastly improved method of identifying protein targets for a given molecule, whether it be a drug candidate, environmental pollutant, or DNA promoter sequence. These protein targets can provide significant improvements to our understanding of the mechanisms of action, side effects, and potential interactions with various tissues that molecules may have. The invention has applications in many areas including pharmaceuticals and personal medicine. DIABLA is cost-effective, helps meet expectations, and hastens FDA submissions.
The US pharmaceutical industry spent over $60 billion on research and development in 2008. Safety issues have had a substantial impact on pharmaceutical development and distribution, and in some cases have caused pharmaceuticals to be removed from the market at great cost. DIABLA can, among other features, provide an efficient way to identify proteins targets systematically while avoiding many costly safety and efficacy problems.
Intellectual Property Status:
U.S. Patent Number 7,931,791, issue date April 26, 2011; additional patents pending.
License Status:
Available for license.
Potential Commercial Uses
- Personalized medicine: People often react differently to the same medicine, and some of this is due to differences in protein binding. A drug could be screened against an individual's proteins to determine how it will affect them.
- Proteomics: useful in the pharmaceutical industry for the discovery of the mechanism of action of pharmaceutical compounds and potential pharmaceutical compounds; useful in the medical field for identifying which pharmaceutical compound may provide the most desirable effects with the fewest side effects for a particular patient.
- Biofuels: for developing better enzymes for converting cellulose into ethanol, useful to determine the effects that a pollutant or contaminant may have on an organism.
Benefits and Competitive Advantages
- High resolution: more than 1100 unique fractions
- Parallel analyses: Simultaneous separation
- Low sample volume: approximately 10mL
- Rapid screens (approximately 20 minutes) for tissue-specific interactions, side effects and individual binding profiles
- Ability to perform separations that are not possible using other methods
- Invention can find active proteins in a complex sample
Brief Description:
The invention provides methods for detecting an interaction between an analyte and a biomolecule. The method comprises separating at least one biomolecule according to its isoelectric point in the presence of a given analyte and detecting an interaction between the analyte and a biomolecule using fluorescence anisotropy. The method may further comprise collecting the analyte-biomolecule complex and analyzing the biomolecule.
More Information:
Dr. Tolley's presentation at SIUC Technology and Innovation Expo - Fall 2010: Summary PDF, Presentation PDF; Summer 2011 Tech Transfer Newsletter Article: DIABLA for Personalized Medicine
Keywords:
Protein identification, protein targets, binding profiles, ligand assays, complex samples, screening for drug efficacy, drug dosage, DIABLA, Proteomics, isoelectric focusing, fluorescence anisotropy, dynamic isoelectric focusing, protein identification, proteomic sample analysis, proteomic research, small molecules, proteins, biomolecules, medicine, pharmaceuticals
Contact:
Jeff Myers, Senior Technology Transfer Specialist, (618) 453-4543, fax: (618) 453-8038
Amy McMorrow Hunter, Technology Transfer Specialist, (618) 453-4556
Sitemap / Contact Us
Comments: Tech Transfer Webmaster | EOE Statement | Privacy Policy
Copyright © 2007-2011, Board of Trustees, Southern Illinois University